DexCom Company Leadership
| DXCM Stock | USD 88.99 2.25 2.59% |
DexCom employs about 10.2 K people. The company is managed by 21 executives with a total tenure of roughly 29 years, averaging almost 1.0 years of service per executive, having 485.71 employees per reported executive. Analysis of DexCom's management performance can provide insight into the firm performance.
| Kevin Sayer CEO CEO and President and Director |
| Andrew Balo President Senior Vice President - Clinical and Regulatory Affairs |
DexCom's latest congressional trading
Congressional trading in companies like DexCom Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in DexCom by those in governmental positions are based on the same information available to the general public.
| 2025-07-09 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2025-06-10 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-05-15 | Representative Michael McCaul | Acquired $50K to $100K | Verify | ||
| 2025-04-29 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-04-18 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2025-03-28 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2020-04-16 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2020-04-15 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2018-07-15 | Representative Bradley S Schneider | Acquired $100K to $250K | Verify |
DexCom Management Team Effectiveness
The company has return on total asset (ROA) of 0.0598 % which means that it generated a profit of $0.0598 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2372 %, meaning that it created $0.2372 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities.DexCom Workforce Comparison
DexCom Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 249,534. DexCom holds roughly 10,200 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13. DexCom Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DexCom insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coleman Jon over three months ago Insider Trading | ||
Heller Bridgette P over three months ago Disposition of 352 shares by Heller Bridgette P of DexCom at 70.33 subject to Rule 16b-3 | ||
Altman Steven R over three months ago Disposition of 2885 shares by Altman Steven R of DexCom subject to Rule 16b-3 | ||
Kevin Sayer over three months ago Acquisition by Kevin Sayer of 68503 shares of DexCom subject to Rule 16b-3 | ||
Heller Bridgette P over six months ago Disposition of 1000 shares by Heller Bridgette P of DexCom at 76.87 subject to Rule 16b-3 | ||
Sadie Stern over six months ago Disposition of 4259 shares by Sadie Stern of DexCom at 74.73 subject to Rule 16b-3 | ||
Altman Steven R over a year ago Acquisition by Altman Steven R of 2613 shares of DexCom subject to Rule 16b-3 | ||
Jacob Leach over a year ago Disposition of 2932 shares by Jacob Leach of DexCom at 121.8505 subject to Rule 16b-3 |
DexCom Notable Stakeholders
A DexCom stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DexCom often face trade-offs trying to please all of them. DexCom's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DexCom's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kevin Sayer | CEO and President and Director | Profile | |
| Andrew Balo | Senior Vice President - Clinical and Regulatory Affairs | Profile | |
| Jereme CPA | CFO VP | Profile | |
| Jacob Leach | Executive COO | Profile | |
| Girish Naganathan | Executive CTO | Profile | |
| Steven Pacelli | Executive VP of Strategy and Corporate Devel. | Profile | |
| Christine Pospisil | Director Education | Profile | |
| Shelly Selvaraj | Senior Officer | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Matthew Dolan | Executive Development | Profile | |
| Teri Lawver | Executive Officer | Profile | |
| Donald Abbey | Quality Services | Profile | |
| Jereme Sylvain | CFO VP | Profile | |
| Paul Flynn | Ex Revenue | Profile | |
| Keri Leone | Senior Education | Profile | |
| Barry Regan | Executive Operations | Profile | |
| Jon Coleman | Executive Officer | Profile | |
| Michael Brown | Executive Officer | Profile | |
| Stacey Stewart | Senior Officer | Profile | |
| Sadie Stern | Executive Officer | Profile | |
| Sean Christensen | Director Relations | Profile |
About DexCom Management Performance
The success or failure of an entity such as DexCom Inc often depends on how effective the management is. DexCom management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DexCom management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DexCom management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people.
DexCom Workforce Analysis
Traditionally, organizations such as DexCom use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DexCom within its industry.DexCom Manpower Efficiency
Return on DexCom Manpower
| Revenue Per Employee | 395.4K | |
| Revenue Per Executive | 192M | |
| Net Income Per Employee | 56.5K | |
| Net Income Per Executive | 27.4M | |
| Working Capital Per Employee | 134.3K | |
| Working Capital Per Executive | 65.2M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.